Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 98

Symplr forges Phynd acquisition

MemorialCare Innovation Fund, Rex Ventures and Orlando Health Ventures are set to exit data management software provider Phynd.

Jan 26, 2021

Taboola tables $2.6bn reverse merger deal

DMGT, Baidu, Advance Publications, Yahoo Japan and Comcast-backed content recommendation software provider Taboola will get an NYSE listing through the deal.

Jan 26, 2021

Latch unlocks public listing with reverse merger

The smart lock provider is merging with a SPAC set up by real estate manager Tishman Speyer, an existing investor, at a $1.56bn post-money valuation.

Jan 26, 2021

Decibel sounds out public markets

The Regeneron, Alphabet and GlaxoSmithKline-backed hearing loss therapy developer has filed to raise up to $75m in its initial public offering.

Jan 26, 2021

Loon comes back down to earth

Google X's balloon internet spinoff is shutting down despite raising $125m from corporate joint venture HapsMobile in 2019.

Jan 25, 2021

Boston Scientific takes care of $925m Preventice acquisition

The medical equipment maker is set to pay as much as $925m to buy its portfolio company that will enable Novo, Merck & Co and Samsung to exit.

Jan 22, 2021

Decipher Biosciences to penetrate public markets

UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.

Jan 22, 2021

Proto Labs locks in 3D Hubs for acquisition

The Hearst Ventures-backed 3D printing marketplace has been acquired by its digital manufacturing services peer Proto Labs in a deal potentially worth $330m.

Jan 22, 2021

NexImmune elects to launch initial public offering

Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Jan 21, 2021

Bolt Biotherapeutics charges to IPO stage

Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

Jan 21, 2021

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here